Piramal Pharma's ESG Rating Hits 64 in Voluntary Agency Report

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
Piramal Pharma's ESG Rating Hits 64 in Voluntary Agency Report
Overview

Piramal Pharma Ltd's Environment, Social, and Governance (ESG) rating has improved to 64 for FY 2024-25, up from 61. The rating was assigned by NSE Sustainability Ratings and Analytics Limited. The company highlighted that the assessment was prepared voluntarily by the agency, suggesting an independent evaluation of its sustainability efforts.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Piramal Pharma's ESG Score Rises to 64 Amid Independent Review

Piramal Pharma Limited has achieved an improved Environment, Social, and Governance (ESG) score of 64 for the fiscal year 2024-25, a rise from its previous rating of 61. The assessment was conducted by NSE Sustainability Ratings and Analytics Limited.

The company noted that NSE Sustainability prepared this rating voluntarily, suggesting an independent evaluation rather than a direct engagement. This follows a similar voluntary report from the agency for FY 2023-24, which also gave Piramal Pharma a score of 61.

Piramal Pharma has been integrating ESG principles into its business strategy, focusing on emissions reduction and waste management, and reported spending ₹5.34 Crore on CSR initiatives for FY2025. The company also secured a score of 63 on the 2025 S&P Global Corporate Sustainability Assessment (CSA), a significant 15% increase from its prior score of 55.

Despite this progress, Piramal Pharma has faced past environmental concerns. These include a closure order for its Digwal plant in 2019 due to pollution allegations and a more recent notice from the Gujarat Pollution Control Board (GPCB) in August 2024 to close its Dahej facility over alleged violations. Such issues could influence future ESG evaluations if not fully resolved.

The broader Indian pharmaceutical sector generally lags global peers in ESG performance, indicating room for industry-wide improvements. Nevertheless, Piramal Pharma's improved ESG score could positively affect investor sentiment, signaling a commitment to sustainable operations. Investors may view the voluntary, independent nature of the NSE rating with credibility, though the company had less direct control over the assessment process.

Piramal Pharma operates in a pharmaceutical landscape where ESG factors are increasingly crucial for investors. Competitors like Aurobindo Pharma, Divi's Laboratories, and Laurus Labs also face ESG scrutiny. Moving forward, investors will likely track Piramal Pharma's future ESG ratings from various agencies, its progress in addressing environmental compliance, and the implementation of its stated ESG initiatives.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.